Abstract
Early diagnosis is a key objective in clinical medicine, and early detection of pathological short stature has tangible benefits for growth prognosis and the well-being of the child. Despite late diagnosis being common in growth disorders, programmes of height screening in primary care are not universal in developed countries and may be random or non-existent. A notable exception is automated growth monitoring in Finland, where an algorithm to detect abnormal growth is integrated into children's electronic health records, resulting in increased diagnoses of pathological short stature. Evidence-based anthropometric criteria for referral of short stature to secondary or tertiary care are now published, due largely to excellent studies in the Netherlands. Following referral of the short child, the protocol for laboratory investigations remains somewhat controversial because in healthy children their diagnostic yield can be too low for cost-effectiveness. However, outside of tertiary academic paediatric endocrinology centres, baseline screening tests are considered worthwhile and may speed up diagnosis and treatment. Finally, auxological cut-offs cannot replace good clinical practice, and the understanding that early and effective management depends on commitment to a diagnosis and individualisation of therapy in the short child cannot be overemphasised.
References
1.
Wit JM, Ranke MB, Albertsson-Wikland K, Carrascosa A, Rosenfeld RG, Van Buuren S, Kristrom B, Schoenau E, Audi L, Hokken-Koelega AC, Bang P, Jung H, Blum WF, Silverman LA, Cohen P, Cianfarani S, Deal C, Clayton PE, de Graaff L, Dahlgren J, Kleintjens J, Roelants M: Personalized approach to growth hormone treatment: clinical use of growth prediction models. Horm Res Paediatr 2013;79:257-270.
2.
Craig D, Fayter D, Stirk L, Crott R: Growth monitoring for short stature: update of a systematic review and economic model. Health Technol Assess 2011;15:iii-iv, 1-64.
3.
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm IGF Res 2008;18:89-110.
4.
Oostdijk W, Grote FK, de Muinck Keizer-Schrama SM, Wit JM: Diagnostic approach in children with short stature. Horm Res 2009;72:206-217.
5.
Wit JM, van Dommelen P, Oostdjik W: Evidence-based guidelines for growth monitoring; in Preedy VR (ed): Handbook of Growth and Growth Monitoring in Health and Disease. New York, Springer, 2012.
6.
Scherdel P, Dunkel L, van Dommelen P, Goulet O, Salaün J-F, Brauner R, Heude B, Chalumeau M: Evidence-based growth monitoring: a systematic review. Lancet 2015, in press.
7.
Fayter D, Nixon J, Hartley S, Rithalia A, Butler G, Rudolf M, Glasziou P, Bland M, Stirk L, Westwood M: A systematic review of the routine monitoring of growth in children of primary school age to identify growth-related conditions. Health Technol Assess 2007;11:1-163.
8.
Ashworth A, Shrimpton R, Jamil K: Growth monitoring and promotion: review of evidence of impact. Matern Child Nutr 2008;4(suppl 1):86-117.
9.
Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009;19:1-11.
10.
Lee PA, Germak J, Gut R, Khutoryansky N, Ross J: Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®. Int J Pediatr Endocrinol 2011;2011:6.
11.
Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH: Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006;91:3897-3902.
12.
van Pareren YK, de Muinck Keizer-Schrama SM, Stijen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwé CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL: Final height in girls with Turner syndrome after long-term hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119-1125.
13.
Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Kerdanet M, Limoni C, Carel JC, Chaussain JL; French Collaborative Young Turner Study Group: Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol 2011;164:891-897.
14.
Stephure DK; Canadian Growth Hormone Advisory Committee: Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360-3366.
15.
Gascoin-Lachambre G, Brauner R, Duche L, Chalumeau M: Pituitary Stalk Interruption Syndrome: Diagnostic Delay and Sensitivity of the Auxological Criteria of the Growth Hormone Research Society. PLoS One 2011;6:e16367.
16.
Huet F, Carel JC, Nivelon JL, Chaussain JL: Long-term results of GH therapy in GH-deficient children treated before 1 year of age. Eur J Endocrinol 1999;140:29-34.
17.
Reiter EO, Price DA, Wilton P, Albertsson-Wikland K, Ranke MB: Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047-2054.
18.
Dahlgren J, Wikland KA; Swedish Study Group for Growth Hormone Treatment: Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005;57:216-222.
19.
Maiorana A, Cianfarani S: Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics 2009;124:e519-e531.
20.
Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO; KIGS International Board: Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm Res 2007;68:53-62.
21.
Wit JM, Reiter EO, Ross JL, Saenger PH, Savage MO, Rogol AD, Cohen P: Idiopathic short stature: management and growth hormone treatment. Growth Horm IGF Res 2008;18:111-135.
22.
Deodati A, Cianfarani S: Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ 2011;342:c7157.
23.
Sawczenko A, Ballinger AB, Savage MO, Sanderson IR: Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006;118:124-129.
24.
Timmer A, Behrens R, Buderus S, Findeisen A, Hauer A, Keller KM, Kliemann G, Lang T, Lohr W, Rzehak P, Koletzko S; CEDATA-GPGE Study Group: Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. J Pediatr 2011;158:467-473.e2.
25.
Bosio L, Barera G, Mistura L, Sassi G, Bianchi C: Growth acceleration and final height after treatment for delayed diagnosis of celiac disease. J Pediatr Gastroenterol Nutr 1990;11:324-329.
26.
Grote FK, Oostdijk W, de Muinck Keizer-Schrama SM, Dekker FW, Verkerk PH, Wit JM: Growth monitoring and diagnostic work-up of short stature: an international inventorization. J Pediatr Endocrinol Metab 2005;18:1031-1038.
27.
Moon JS: Secular trends of body sizes in Korean children and adolescents: from 1965 to 2010. Korean J Pediatr 2011;54:436-442.
28.
Grote FK, van Dommelen P, Oostdijk W, de Muinck Keizer-Schrama SM, Verkerk PH, Wit JM, van Buuren S: Developing evidence-based guidelines for referral for short stature. Arch Dis Child 2008;93:212-217.
29.
Voss LD, Mulligan J, Betts PR, Wilkin TJ: Poor growth in school entrants as an index of organic disease: the Wessex growth study. BMJ 1992;305:1400-1402.
30.
Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M: Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994;125:29-35.
31.
Grote FK, Oostdijk W, De Muinck Keizer-Schrama SM, van Dommelen P, van Buuren S, Dekker FW, Ketel AG, Moll HA, Wit JM: The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines. BMC Pediatr 2008;8:21.
32.
de Muinck Keizer-Schrama SM: Consensus ‘diagnosis of short stature in children.' National Organization for Quality Assurance in Hospitals. Ned Tijdschr Geneeskd 1998;142:2519-2525.
33.
van Buuren S, Bonnemaijer-Kerckhoffs DJ, Grote FK, Wit JM, Verkerk PH: Many referrals under Dutch short stature guidelines. Arch Dis Child 2004;89:351-352.
34.
Stalman SE, Hellinga I, van Dommelen P, Hennekam RC, Saari A, Sankilampi U, Dunkel L, Wit JM, Kamp GA, Plötz FB: Application of the Dutch, Finnish and British screening guidelines in a cohort of children with growth failure. Horm Res Paediatr DOI: 10.1159/000440652.
35.
Sankilampi U, Saari A, Laine T, Miettinen PJ, Dunkel L: Use of electronic health records for automated screening of growth disorders in primary care. JAMA 2013;310:1071-1072.
36.
Wit JM, Ranke MB, Kelnar CJH: ESPE Classification of Paediatric Endocrine Diagnoses. Horm Res 2007;68(suppl 2):1-120.
37.
Saari A, Harju S, Mäkitie O, Saha M-T, Dunkel L, Sankilampi U: Systematic growth monitoring for the early detection of celiac disease in children. JAMA Pediatr 2015;169:e1525.
38.
Scherdel P, Salaün JF, Robberecht-Riquet MN, Reali L, Páll G, Jäger-Roman E, Crespo MP, Moretto M, Seher-Zupančič M, Agustsson S; European Confederation of Primary Care Paediatricians Research Group, Chalumeau M: Growth monitoring: a survey of current practices of primary care paediatricians in Europe. PLoS One 2013;8:e70871.
39.
van Dommelen P, Schönbeck Y, van Buuren S: A simple calculation of the target height. Arch Dis Child 2012;97:182.
40.
World Health Organization: WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Developments. Geneva, World Health Organization, 2006.
41.
Silventoinen K, Sammalisto S, Perola M, Boomsma DI, Cornes BK, Davis C, Dunkel L, de Lange M, Harris JR, Hjelmborg JV, Luciano M, Martin NG, Mortensen J, Nisticò L, Pedersen NL, Skytthe A, Spector TD, Stazi MA, Willemsen G, Kaprio J: Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res 2003;6:399-408.
42.
Saari A, Sankilampi U, Hannila ML, Kiviniemi V, Kesseli K, Dunkel L: New Finnish growth references for children and adults aged 0 to 20 years: length/height-for-age, weight-for-length/height, and body mass index-for-age. Ann Med 2011;43:235-248.
43.
Saari A, Sankilampi U, Hannila ML, Saha MT, Makitie O, Dunkel L: Screening of Turner syndrome with novel auxological criteria facilitates early diagnosis. J Clin Endocrinol Metab 2012;97:E2125-E2132.
44.
Saari A, Sankilampi U, Dunkel L: Multiethnic WHO growth charts may not be optimal in the screening of disorders affecting height: Turner syndrome as a model. JAMA Pediatr 2013;167:194-195.
45.
Machogu E, Cao Y, Miller T, Simpson P, Levy H, Quintero D, Goday PS: Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis. J Pediatr 2015;60:378-383.
46.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM, on behalf of the 2007 ISS Consensus Workshop participants: Consensus Statement on Diagnosis and Treatment of Children with Idiopathic Short Stature. A summary of the GRS/LWPES/ESPE Workshop. J Clin Endocrinol Metab 2008;93:4210-4217.
47.
Savage MO, Burren CP, Rosenfeld RG: The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf) 2010;72:721-728.
48.
Cummins AG, Roberts-Thomson IC: Prevalence of coeliac disease in the Asia-Pacific region. J Gastroenterol Hepatol 2009;24:1347-1351.
49.
Sisley S, Vargas Trujillo M, Khoury J, Backeljauw PF: Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr 2013;163:1045-1051.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
